DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role… Read More
UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players… Read More
Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME). The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in… Read More
